As filed with the Securities and Exchange Commission on March 31, 2023

Registration No. 333-

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

SCYNEXIS, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

 

 

 

 

 

 

Delaware

 

56-2181648

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

1 Evertrust Plaza, 13th Floor

Jersey City, New Jersey 07302-6548

(201) 884-5485

(Address of principal executive offices) (Zip code)

 

 

SCYNEXIS, Inc. 2014 Equity Incentive Plan

SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan

(Full title of the plan)

 

 

David Angulo, M.D.

Chief Executive Officer

SCYNEXIS, Inc.

1 Evetrust Plaza, 13th Floor

Jersey City, NJ 07302-6548

(201) 884-5485

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Matthew B. Hemington

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

(650) 843-5000

 


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

Emerging growth company

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 


EXPLANATORY NOTE

 

SCYNEXIS, Inc. (the “Registrant ”) is filing this Registration Statement on Form S-8 for the purpose of registering an aggregate of 1,904,901 additional shares of its Common Stock, issuable to eligible persons under the SCYNEXIS, Inc. 2014 Equity Incentive Plan and the SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan (collectively, the “Plans” ), which Common Stock is in addition to the shares of Common Stock previously registered on the following Form S-8s (collectively, the “Prior Form S-8s” ) pursuant to the Plans:

the Registrant’s Form S-8 filed on May 16, 2014 (File No. 333-196007);
the Registrant’s Form S-8 filed on December 18, 2014 (File No. 333-201048);
the Registrant’s Form S-8 filed on March 17, 2015 (File No. 333-202830);
the Registrant’s Form S-8 filed on June 6, 2015 (File No. 333-204771);
the Registrant's Form S-8 filed on March 7, 2016 (File No. 333-209997);
the Registrant's Form S-8 filed on March 13, 2017 (File No. 333-216652);
the Registrant's Form S-8 filed on March 13, 2018 (File No. 333-223624);
the Registrant's Form S-8 filed on March 14, 2019 (File No. 333-230278);
the Registrant's Form S-8 filed on March 11, 2020 (File No. 333-237077);
the Registrant’s Form S-8 filed on March 29, 2021 (File No. 333-254831); and
the Registrant’s Form S-8 filed on March 30, 2022 (File No. 333-263962).

Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8s are incorporated herein by reference and made a part hereof.

 

PART II

 

Item 3. Incorporation of Documents by Reference.

The following documents filed by SCYNEXIS, Inc. (the “Registrant”) with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:

(a) The Registrant’s Annual Report on Form 10-K filed on March 31, 2023.

(b) The Registrant’s Current Report on Form 8-K filed on March 30, 2023.

(c) The description of the Registrant’s common stock which is contained in the registration statement on Form 8-A filed on March 19, 2014, (File No. 001-36365) under the Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed on March 29, 2022.

(d) The other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits

Exhibit

Number

 

Description

 

 

4.1

 

Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc., as currently in effect (Filed as Exhibit 3.1 to Registrant’s Current Report on Form 8-K (File No. 001-36365), filed with the Securities and Exchange Commission on May 12, 2014, and incorporated herein by reference).

 

 

 

4.2

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, In. (Filed with the SEC as Exhibit 3.2 to our Form 10-Q, filed with the SEC on August 7, 2019, SEC File No. 001-36365, and incorporated by reference here).

 

 

4.3

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.1 to our Form 8-K, filed with the SEC on July 16, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 


4.4

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.4 to our Form 10-Q, filed with the SEC on November 9, 2022, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

4.5

 

Amended and Restated Bylaws of SCYNEXIS, Inc., as currently in effect (Filed as Exhibit 3.4 to Registrant’s Registration Statement on Form S-1 (File No. 333-194192), filed with the Securities and Exchange Commission on February 27, 2014, and incorporated herein by reference).

 

 

5.1

 

Opinion of Cooley LLP.

 

 

23.1

 

Consent of Cooley LLP (included in Exhibit 5.1).

 

 

23.2

 

Consent of Independent Registered Public Accounting Firm.

 

 

24.1

 

Power of Attorney (included on the signature page of this Form S-8).

 

 

99.3

 

SCYNEXIS, Inc. 2014 Equity Incentive Plan (Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q (File No. 001-36365), filed with the Securities and Exchange Commission on August 10, 2020, and incorporated herein by reference).

 

 

99.4

 

 

SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan (Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q (File No. 001-36365), filed with the Securities and Exchange Commission on August 10, 2020, and incorporated herein by reference).

 

 

 

107

 

Filing Fee Table


 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jersey City, State of New Jersey, on this 29th day of March, 2023.

 

SCYNEXIS, INC.

 

 

By:

 

/s/ David Angulo

 

 

David Angulo, M.D.

 

 

Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoint David Angulo, M.D. and Scott Sukenick, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signatures

 

 

 

Title

 

Date

 

 

 

 

/s/ David Angulo, M.D.

 

 

 

Director, Chief Executive Officer and President (Principal Executive Officer)

 

March 29, 2023

David Angulo, M.D.

 

 

 

 

 

 

 

 

 

 

/s/ Ivor Macleod

 

 

 

Chief Financial Officer

(Principal Financial and Accounting Officer )

 

March 30, 2023

Ivor Macleod

 

 

 

 

 

 

 

 

 

 

/s/ Guy Macdonald

 

 

 

Chairman of the Board of Directors

 

March 29, 2023

Guy Macdonald

 

 

 

 

 

 

 

 

 

 

/s/ Armando Anido

 

 

 

Director

 

March 29, 2023

Armando Anido

 

 

 

 

 

 

 

 

 

 

/s/ Steven C. Gilman

 

 

 

Director

 

March 30, 2023

Steven C. Gilman, Ph.D.

 

 

 

 

 

 

 

 

 

 

/s/ Ann F. Hanham

 

 

 

Director

 

March 29, 2023

Ann F. Hanham, Ph.D.

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ David Hastings

 

 

 

Director

 

March 30, 2023

David Hastings

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Brian Philippe Tinmouth

 

 

 

Director

 

March 29, 2023

Brian Philippe Tinmouth